References
- Deurenberg RH, Stobberingh EE. The evolution of Staphylococcus aureus. Infect. Genet. Evol.8(6), 747–763 (2008).
- Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis.40(4), 562–573 (2005).
- Sheagren JN. Staphylococcus aureus. The persistent pathogen (second of two parts). N. Engl. J. Med.310(22), 1437–1442 (1984).
- Community-acquired methicillin-resistant Staphylococcus aureus infections – Michigan. MMWR Morb. Mortal. Wkly Rep.30(16), 185–187 (1981).
- Davis SL, Perri MB, Donabedian SM et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J. Clin. Microbiol.45(6), 1705–1711 (2007).
- Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st Century – a clinical super-challenge. N. Engl. J. Med.360(5), 439–443 (2009).
- Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis.52(3), 285–292 (2011).
- Nannini E, Murray BE, Arias CA. Resistance or decreased susceptibility to glycopeptides, daptomycin, and linezolid in methicillin-resistant Staphylococcus aureus. Curr. Opin. Pharmacol.10(5), 516–521 (2010).
- Moise PA, Smyth DS, El-Fawal N et al. Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother.61(1), 85–90 (2008).
- Gleeson TD. Prevention and control of methicillin-resistant Staphylococcus aureus. Dis. Mon.54(12), 801–806 (2008).
- Siegel JD, Rhinehart E, Jackson M, Chiarello L. Healthcare Infection Control Practices Advisory Committee. management of multidrug-resistant organisms in health care settings, 2006. Am. J. Infect. Control.35(10 Suppl. 2), S165–S193 (2007).
- Garner P, Kale R, Dickson R, Dans T, Salinas R. Getting research findings into practice: implementing research findings in developing countries. Br. Med. J.317(7157), 531–535 (1998).
- Steed ME, Rybak MJ. Ceftaroline: a new cephalosporin with activity against resistant Gram-positive pathogens. Pharmacotherapy30(4), 375–389 (2010).
- Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy26(4), 539–550 (2006).
- Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother.10(3), 146–156 (2004).